Patient-derived tumoroids and proteomic signatures: tools for early drug discovery.
Saved in:
| Title: | Patient-derived tumoroids and proteomic signatures: tools for early drug discovery. |
|---|---|
| Authors: | Lê H; Transgene S.A., Illkirch-Graffenstaden, France.; INSERM UMR1260, Regenerative Nanomedicine, Strasbourg, France., Deforges J; Transgene S.A., Illkirch-Graffenstaden, France., Cutolo P; Olink, Uppsala, Sweden., Lamarque A; Olink, Uppsala, Sweden., Hua G; INSERM UMR1260, Regenerative Nanomedicine, Strasbourg, France., Lindner V; INSERM UMR1260, Regenerative Nanomedicine, Strasbourg, France.; Department of Pathology, Hopitaux Universitaires de Strasbourg, Strasbourg, France., Jain S; Transgene S.A., Illkirch-Graffenstaden, France., Balloul JM; Transgene S.A., Illkirch-Graffenstaden, France., Benkirane-Jessel N; INSERM UMR1260, Regenerative Nanomedicine, Strasbourg, France., Quéméneur E; Transgene S.A., Illkirch-Graffenstaden, France. |
| Source: | Frontiers in immunology [Front Immunol] 2024 Apr 18; Vol. 15, pp. 1379613. Date of Electronic Publication: 2024 Apr 18 (Print Publication: 2024). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1379613 |
